C-CAR031
AstraZeneca Acquires Complete Global Rights to AbelZeta’s C-CAR031 CAR-T Therapy for Up to $630 Million
AstraZeneca; AbelZeta; C-CAR031; CAR-T; GPC3; China rights; $630M; hepatocellular carcinoma; HCC
Actionable Insights Powered by AI
AstraZeneca; AbelZeta; C-CAR031; CAR-T; GPC3; China rights; $630M; hepatocellular carcinoma; HCC